Chronic Lymphocytic Leukemia

Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.

During a Targeted Oncology case-based roundtable event, Susan O'Brien, MD, discussed the case of a 71-year-old woman newly diagnosed with chronic lymphocytic leukemia.

With roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without obinutuzumab vs obinutuzumab and chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.

John F. Seymour, MBBS, PhD, discusses the results of a post-hoc analysis of adverse events in the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Nakhle Saba, MD, reviewed testing, treatment, and treatment toxicity in a 71-year-old woman with chronic lymphocytic leukemia with a group of peers during a Targeted Oncology case-based roundtable event.

Dosing of NX-2127 in patients with chronic lymphocytic leukemia has begun in a phase 1b clinical trial.

Targeted agents, such as Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and venetoclax, have delivered improvements in quality of life, progression-free survival, and overall survival for relapsed/refractory chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Wojciech Jurczak, MD, PhD, discussed the clinical trial investigation of ceralasertib with or without acalabrutinib in patients with high-risk relapsed or refractory chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.

During a Targeted Oncology case-based event, Lindsey Roeker, MD, discussed risk assessment and frontline therapy for a patient diagnosed with chronic lymphocytic leukemia.

John F. Seymour, MBBS, PhD, discusses the rationale for a post-hoc analysis of the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

John Allan, MD, speaks to the exciting future of treatments for chronic lymphocytic leukemia.

Dr John Allan discusses the adverse events he monitors for with select treatments for chronic lymphocytic leukemia, and when he decides to move to second-line therapy.

An expert in hematologic malignancies describes how he would monitor a patient on frontline treatment with newly diagnosed chronic lymphocytic leukemia.

John Allan, MD, explains how fitness level and comorbidities affect his treatment selections for chronic lymphocytic leukemia and whether he prefers fixed-duration or continuous-strategy approaches.

Dr John Allan gives an overview of the frontline treatment options available for chronic lymphocytic leukemia with reference to clinical trial data.

A leukemia expert discusses ongoing challenges in chronic lymphocytic leukemia treatment, and how to discuss risk stratification with a patient.

John Allan, MD, presents the case of a 70-year-old woman with newly diagnosed chronic lymphocytic leukemia.

With an increasing imbalance in overall survival, the FDA approval application for the combination of ublituximab and umbralisib for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdrawn.

The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.

Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.

Jennifer Brown, MD, PhD discusses the purpose of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia.

Research results suggest that CAR T-cell therapy can overcome T cell defects caused by chronic lymphocytic leukemia, with remissions possibly lasting more than a decade for patients with significant disease burden when treated with CD4+ CAR T cells

Venetoclax consolidation after 12-cycles of treatment increases the duration of known toxicities and does not prevent the loss of minimal residual disease response and subsequent risk of disease relapse in patients with previously untreated chronic lymphocytic leukemia, a study shows.

Successful CAR T-cell production was achieved in all 11 patients who underwent apheresis and cell production but were still alive at the time of infusion, according to result presented during the BMT- EHA 4th European CAR T-Cell Meeting.

The FDA will now make a decision on the approval application for ublituximab/umbralisib in chronic lymphocytic leukemia and small lymphocytic lymphoma in June following an ODAC meeting.

Even with the available agents and knowledge of when to select which option, there is an unmet medical need in the chronic lymphocytic leukemia landscape, according to Jennifer R. Brown, MD, PhD.

Data supporting zanubrutinib for the treatment of chronic lymphocytic leukemia or small lymphocytic leukemia will undergo a regular FDA review in consideration for FDA approval.

During a Targeted Oncology case-based roundtable event, Farrukh Awan, MD, discussed the data supporting treatments for chronic lymphocytic leukemia including venetoclax and obinutuzumab, acalabrutinib, and ibrutinib.